Skip to main content
. 2021 Mar 19;40(16):2872–2883. doi: 10.1038/s41388-021-01720-w

Fig. 1. LXR ligands induce chemoresistance in triple negative breast cancer cell lines.

Fig. 1

MTT assay of epirubicin dose response following pre-treatment of MDA.MB.468 and MDA.MB.231 cell lines with low, medium, and high doses of LXR agonists (A) or antagonist (B). Data shown are mean with SEM of three independent replicates each performed with six technical replicates. Statistical significance was determined using non-linear regression curve comparison against epirubicin (EPI) only curve. Colony Forming Assays measuring how the ability of MDA.MB.468 and MDA.MB.231 cell lines to generate colonies after epirubicin exposure is improved by pre-treating cells with LXR agonists (C) or antagonist (D). Three or four independent replicates were performed (as indicated), each independent replicate is the mean of three technical repeats. p values were calculated using paired t test.